GH Research PLC
GHRS13.125USD
-0.295-2.20%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
788.02MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über GH Research PLC Unternehmen
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Unternehmensinformationen
BörsenkürzelGHRS
Name des UnternehmensGH Research PLC
IPO-datumJun 25, 2021
CEODr. Velichka (Villy) Valcheva, M.D.
Anzahl der mitarbeiter50
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
AddresseJoshua Dawson House
StadtDUBLIN
BörseNASDAQ Global Market Consolidated
LandIreland
PostleitzahlD02 RY95
Telefon35314378334
Website
BörsenkürzelGHRS
IPO-datumJun 25, 2021
CEODr. Velichka (Villy) Valcheva, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
12.38%
Lynx1 Capital Advisors LLC
10.88%
RTW Investments L.P.
8.93%
Andere
29.68%
Aktionäre
Aktionäre
Anteil
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
12.38%
Lynx1 Capital Advisors LLC
10.88%
RTW Investments L.P.
8.93%
Andere
29.68%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
31.46%
Hedge Fund
22.53%
Investment Advisor
20.55%
Venture Capital
13.30%
Investment Advisor/Hedge Fund
9.66%
Research Firm
4.38%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
81
63.73M
102.74%
+7.16M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
2023Q1
76
51.21M
98.45%
-5.44M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
-1.57M
-15.12%
Mar 31, 2025
RA Capital Management, LP
6.94M
11.2%
+257.96K
+3.86%
Mar 31, 2025
Lynx1 Capital Advisors LLC
6.44M
10.39%
+90.87K
+1.43%
Mar 31, 2025
RTW Investments L.P.
5.50M
8.87%
+2.17M
+65.30%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.25M
6.85%
+1.76M
+70.85%
Mar 31, 2025
Terwey (Theis)
6.19M
9.98%
--
--
Dec 31, 2024
Cormorant Asset Management, LP
2.01M
3.24%
+1.42M
+238.84%
Mar 31, 2025
Deep Track Capital LP
2.00M
3.22%
+2.00M
--
Mar 31, 2025
TD Securities, Inc.
1.97M
3.17%
+1.97M
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
AdvisorShares Psychedelics ETF
4.69%
Virtus LifeSci Biotech Clinical Trials ETF
1.32%
iShares MSCI Ireland ETF
1.03%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
Anteil4.69%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.32%
iShares MSCI Ireland ETF
Anteil1.03%
SPDR S&P International Small Cap ETF
Anteil0.02%
ALPS Medical Breakthroughs ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
